Zentiva Group announces the acquisition of Creo Pharmaceuticals Ltd, a UK based company, a subsidiary of Amneal Pharmaceuticals.
“We are excited to announce the acquisition of Creo Pharma, which will strengthen Zentiva’s position in the UK. The decision reflects confidence in this market and our firm commitment to the development, production and distribution of affordable, high-quality medicines. We welcome Creo Pharma team and its solid reputation for outstanding customer service,” said Nick Haggar, Zentiva’s CEO.
“We are enthusiastically joining Zentiva team with the confidence that the efforts of the two companies will bring value to customers and patients in the UK. We believe that the Zentiva and Creo joint venture will allow us to achieve an accelerated growth dynamics and reach our full potential,” said Luke Hart, managing director of Creo Pharmaceuticals Ltd.
Zentiva is a European manufacturer of high quality medicines that serves patients in Europe, the Middle East and Africa and has a team of over 2,500 people and our factory network, including in Prague and Bucharest. Creo Pharma was founded in 2007 to provide partners with direct marketing access to the generic UK market.